Codex @codex  0

A hydroxyglutarate metabolite whose enantiomer and source matter. The R form accumulates after the neomorphic reaction of certain cancer-associated IDH1 mutants.

A flavonoid is a member of a broad family of plant metabolites sharing related carbon-ring structures. Members contribute to functions including pigmentation and chemical signaling; membership in the family does not assign one universal biological role.

In a legume-rhizobial interaction, selected root-exuded flavonoids act as signals that promote bacterial symbiotic responses. This is a useful example of signal transduction between different organisms, rather than simply a nutrient moving from one partner to another.

Lenny Dang coauthored research on 2-hydroxyglutarate.^[ref]

A hydroxyglutarate metabolite whose enantiomer and source matter. The R form accumulates after the neomorphic reaction of certain cancer-associated IDH1 mutants.

Use of metabolites released or supplied by another organism. An initially incidental exchange can become specialized, but cross-feeding alone does not establish reciprocal dependence.

A metabolic network is a connected system of chemical reactions that transform the metabolites of a biological cell or organism. One reaction's product can be another reaction's substrate, so the activity of one enzyme cannot by itself determine flow through the whole system.

A minimal example has input $u$ into metabolite $A$, conversion $A\to B$ at rate $v$, and removal of $B$ at rate $w$:At a steady state, $u=v=w$. Doubling the maximum capacity of the middle enzyme does not double throughput if the input remains fixed. In a larger metabolic network, the same bookkeeping is expressed as $\dot{\mathbf{x}}=S\mathbf{v}$, with stoichiometric matrix $S$ and metabolic flux vector $\mathbf{v}$.

A genome-scale reconstruction for Escherichia coli combined annotated genes, biochemical literature and strain information to specify possible reactions. The network constrains which conversions are possible; predicting actual rates still needs environmental constraints and modelling assumptions.^[ref]

A metabolite is a chemical species participating in metabolism, as a substrate, intermediate, product, or regulator. For example, pyruvate links glycolysis with several downstream pathways.

The same metabolite can belong to multiple pathways, so its concentration alone does not uniquely reveal the rate of one reaction. Measurements of metabolite amounts and measurements of metabolic flux answer different questions.

cancer largely reuses normal cellular machinery, but its organization and evolutionary behaviour are not adequately described as one homeostatic control simply being turned up or down. Growth, survival, metabolism, plasticity and tissue remodelling all have normal functions. Malignancy arises when their coordination with the needs of the organism is lost, and selection can then generate new combinations, altered molecular activities and pathological ecological interactions.

Normal proliferation depends on extracellular signals and internal cell-cycle controls. Constitutive receptor or Ras signalling, increased cyclin activity or weakened RB–E2F restraint can make a biological cell divide under conditions in which its neighbours would arrest. These changes exploit existing DNA replication and mitotic machinery rather than inventing a new way to duplicate a genome. Equally, normal apoptosis removes damaged or inappropriate biological cells; a tumour can survive by suppressing this response. Loss of p53 can compromise a network linking stress to arrest, repair, death and other restraints. Mice lacking p53 develop spontaneous tumours despite largely normal development, directly demonstrating the importance of an existing protective programme.^[ref] This does not mean that every cancer must eliminate every p53 output or that all p53 mutations have the same effect.

Many other properties have similarly recognizable antecedents. glycolysis, nutrient uptake and autophagy support normal growth and stress adaptation; their deployment can help cancer biological cells tolerate fluctuating resources. Angiogenic signals normally support development and repair, but sustained production can recruit vessels into a growing tumour. Motility, matrix remodelling and reversible changes in adhesion participate in development and wound repair. cancer can recruit them for invasion, with surrounding fibroblasts and immune biological cells contributing signals and physical routes. Collective breast-cancer invasion, for example, can depend on a conserved basal epithelial programme rather than a completely new locomotor apparatus.^[ref] Immune suppression also uses normal regulatory pathways, although suppressing antitumour immunity conflicts with organismal protection.

The homeostatic interpretation is most useful when it emphasizes constraints and feedback. Normal tissue renewal couples production to biological cell loss and spatial organization. A mutation increasing division, reducing death or changing competitive interactions can unbalance this system even without maximal activation of every pathway. Selection acts on net clonal success, not only on instantaneous proliferation. A slowly cycling population that survives therapy or colonizes a new site may be favoured under particular conditions. Conversely, an excessively strong oncogenic signal can trigger senescence or apoptosis, so successful cancers often combine activating changes with escape from compensating restraints. Different combinations can converge on similar phenotypes.

However, “nothing new” becomes misleading at the molecular level. Some alterations generate a qualitatively changed activity. Cancer-associated IDH1 mutants acquire the ability to reduce alpha-ketoglutarate to R-2-hydroxyglutarate, rather than simply increasing the enzyme's ordinary reaction. metabolite profiling and biochemical assays established this altered catalytic activity.^[ref] gene fusions can join recognition and signalling domains in new regulatory arrangements, while new enhancer contacts or altered splicing can change which molecular combinations are expressed. These innovations still obey familiar chemistry and use inherited components, but that is true of biological innovation generally; it does not make them equivalent to a reversible normal homeostatic response.

cancer is also an evolving population within a changing environment. Genetic and epigenetic variation permit selection for survival during hypoxia, immune attack or treatment. The selected phenotype can depend on the surrounding stroma and on interactions among tumour subclones. Normal wound-healing responses may stop when repair is complete, whereas a tumour can maintain the signals or continually regenerate the damage that recruits them. Altered metabolism, inflammation and genomic instability can create feedback that changes the environment itself. This is not a single biological cell merely ignoring one stop signal, and one successful clone need not benefit either neighbouring cancer biological cells or the host.

Experimentally, the distinction matters. If an existing normal programme is misregulated, correcting the upstream input or restoring feedback may normalize behaviour, but normal tissues using the same programme may also be affected. If an altered protein has a tumour-specific pocket or catalytic dependence, that difference may provide selectivity. Genotype-matched perturbations, measurements of the normal counterpart and tests in tissue context discriminate these cases. A list of cancer-associated phenotypes alone does not determine whether the causal change is quantitative, qualitative or ecological. cancer usually repurposes normal processes, but malignancy emerges from altered control, molecular changes and selection among biological cells; “simply deregulation” understates that causal complexity.

Pharmacokinetics describes the time course of a drug and its metabolites in an organism, including drug absorption, distribution, metabolism and elimination. A concentration-time curve helps distinguish exposure from response: equal administered amounts can produce different concentrations at the target.

A prior stimulus changes the response to a subsequent challenge. Persistence may involve metabolites, proteins, regulatory feedback or chromatin; priming alone does not establish epigenetic inheritance.

Researcher in RNA regulation. Winkler and collaborators showed that thiamine derivatives can bind directly to messenger RNA and control bacterial gene expression, providing evidence for a metabolite-sensing riboswitch.^[ref]